[
astrazeneca
]
Covishield: A timeline of the Covid-19 vaccine manufactured by SII
By hindustantimes.com | Written by Srivatsan K C
UPDATED ON JAN 16, 2021 11:21 PM IST
Pune-based Serum Institute of India partnered with the Oxford University to manufacture their Covishield vaccine in India.
Covid-19 vaccination: Second pan-India dry run today, Chinese vaccine found 78% effective in Brazil
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON JAN 08, 2021 09:26 AM IST
Immunisation drives against Covid-19 are currently underway in several countries. Vaccines developed by Pfizer-BioNTech SE and Moderna are being most widely used.
Britain working with Pfizer, AstraZeneca to increase vaccine supplies
By Reuters | Posted by Mallika Soni | London
UPDATED ON JAN 07, 2021 09:11 PM IST
More than 1.3 million people in the United Kingdom have received one shot of either AstraZeneca’s or Pfizer’s Covid-19 vaccine, but the government needs to be administering around 2 million doses a week to hit its February target.
Ireland sees delivery of at least 470,000 Covid-19 vaccine doses in Q1
By Reuters| Posted by Mallika Soni | Dublin
PUBLISHED ON JAN 07, 2021 02:53 PM IST
Ireland, which has a population of 4.9 million, has confirmed orders for 360,000 doses of the Pfizer/BioNTech Covid-19 vaccine and for 110,000 doses of the rival Moderna vaccine, Health Minister Stephen Donnelly told RTE radio.
Vaccine pricing still a sticking point?
By HT Correspondent | Hindustan Times, New Delhi
UPDATED ON JAN 07, 2021 06:28 AM IST
Union health secretary Rajesh Bhushan said on Tuesday said that the vaccination drive in India will begin 10 days after two vaccines, the one manufacture by SII and Bharat Biotech’s Covaxin, received emergency use authorisation
Timeline: How EU filled its basket in Covid-19 vaccine shopping spree
By Reuters | Posted by Kunal Gaurav | Brussels
PUBLISHED ON JAN 06, 2021 07:54 PM IST
In June, the EU set up a team of experts from the bloc’s 27 member states to negotiate together with vaccine makers the advance purchase of Covid-19 shots, with a budget of about $2.4 billion.
Covid-19: UK begins immunisation drive of second vaccine, Mexico okays Oxford-AstraZeneca candidate
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON JAN 05, 2021 08:54 AM IST
Israel has become the third country, after the United States and Canada, to approve Moderna’s Covid-19 vaccine, the American drugmaker said on Monday.
Sensex resumes rally, soars past 48,000
By Nasrin Sultana | Livemint
UPDATED ON JAN 05, 2021 07:16 AM IST
“World stock markets hit record highs on Monday, the first trading day of the new year, as investors hoped the rollout of vaccines would ultimately lift a global economy ruined by the pandemic. The post holiday upbeat mood in India should sustain for 1-2 sessions,” Deepak Jasani, head of retail research, HDFC Securities said.
UK rolls out AstraZeneca Covid-19 vaccine; 82-year-old gets first shot
By hindustantimes.com | Edited by Srivatsan K C | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 05:07 PM IST
“I am so pleased to be getting the COVID vaccine today and really proud that it is one that was invented in Oxford,” 82-year-old Brian Pinker said after receiving the vaccine.
Covishield vaccine to be sold to govt at Rs 200/ dose, higher price for private buyers, says Adar Poonawalla
By Associated Press | Posted by Arpan Rai | New Delhi
UPDATED ON JAN 04, 2021 09:56 AM IST
With rich nations reserving most of the vaccines that will be made this year, Serum Institute — the world’s largest vaccine manufacturer — is likely to make most of the inoculations for developing countries.
Covid-19: India approves first 2 vaccines, UK to begin another immunisation drive
By hindustantimes.com | Edited by Karan Manral | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 09:23 AM IST
Brazil might procure vaccines from India while Jordan announces deal for three million doses.
Experts flag concern over ‘limited data’ for Covaxin
By Sanchita Sharma | Hindustan Times, New Delhi
UPDATED ON JAN 04, 2021 02:41 AM IST
Early-stage trials found the vaccine to be safe and able to invoke a robust immune response, but Phase 2 data is under peer review and has not been published. Phase 3 trials were announced on November 16, and around 22,500 of 25,800 volunteers have enrolled of which around half have received two doses.
Video of Egypt virus patients’ ICU death stirs controversy
By Associated Press | Posted by Kunal Gaurav | Cairo
PUBLISHED ON JAN 03, 2021 09:37 PM IST
The governor of Sharqia province denied allegations by a relative of one of the patients that the deaths were caused by a lack of oxygen at the government-run intensive care unit treating Covid-19 patients.
SII to meet local demand for Oxford vaccine for next 2 months, before exporting
By Reuters | Posted by Kanishka Sarkar | New Delhi
PUBLISHED ON JAN 03, 2021 09:13 PM IST
SII is still waiting to strike a formal supply deal with the government, but is expected to do so in the coming days.
DCGI gives licensing permission to Bharat Biotech to manufacture Covaxin
By hindustantimes.com| Edited by Susmita Pakrasi | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:58 PM IST
The DCGI gave final approval to two Covid-19 vaccines, paving the way for a huge inoculation program to stem the pandemic in the second worst-hit country.
‘Disgraceful’: Health minister Vardhan slams Akhilesh Yadav, Tharoor over Covid-19 vaccine ‘doubts’
By hindustantimes.com| Edited by Susmita Pakrasi | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:41 PM IST
The DCGI gave approval for the emergency use of two Covid-19 vaccines, one developed by AstraZeneca and Oxford University and the other by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
Mixing of Covid-19 vaccines: Where do health agencies stand?
By hindustantimes.com | Edited by Kunal Gaurav | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 05:37 PM IST
The UK government’s vaccine guidance contradicts the norms published by the US Centers for Disease Control and Prevention (CDC) for two Covid-19 vaccines authorised by the Food and Drug Administration.
Bharat Biotech’s Covaxin can be used as backup, says AIIMS Director Dr Randeep Guleria
By hindustantimes.com | Edited by Shivani Kumar | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 06:32 PM IST
The DCGI gave approval for the emergency use of two Covid-19 vaccines, one developed by AstraZeneca and Oxford University and the other by Hyderabad-based Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and National Institute of Virology (NIV).
AstraZeneca-Oxford Covid-19 vaccine: What’s been said about dosage, efficacy
By Reuters | Posted by Kanishka Sarkar | Reuters
UPDATED ON JAN 03, 2021 03:13 PM IST
Authorities in Britain, the first to have authorised the Covid-19 vaccine, on Wednesday recommended giving as many people as possible a first dose right away and following up with a second injection four to 12 weeks later.
WHO welcomes India’s decision giving emergency use approval to Covid-19 vaccines
By hindustantimes.com| Edited by Susmita Pakrasi | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 01:40 PM IST
Drugs Controller General of India VG Somani has formally announced the approval for the emergency-use of two coronavirus vaccines, one developed by AstraZeneca and Oxford University and the other by local company Bharat Biotech.
Covishield vs Covaxin against Covid-19: All you need to know
By hindustantimes.com | Edited by Poulomi Ghosh | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 08:33 PM IST
With more than one vaccine now approved for emergency use, the scope of India’s first phase vaccination in which the frontline workers will be vaccinated at free of cost gets widened.
Russia to trial combined AstraZeneca, Sputnik V vaccine in Ukraine
By Reuters | Moscow
UPDATED ON JAN 03, 2021 09:02 AM IST
Russia’s sovereign RDIF announced in December trials to test a combination of the AstraZeneca vaccine with the Sputnik V shot to see if this can boost the efficacy of the British drugmaker’s vaccine.
Expert panel gives nod to Covaxin for restricted use
By Rhythma Kaul | Hindustan Times, New Delhi
UPDATED ON JAN 03, 2021 12:19 AM IST
The Bharat Biotech vaccine, known as Covaxin, is in phase III trials that began in mid-November. The SEC recommended it be given permission “for restricted use in emergency situation in public interest as an abundant precaution, in clinical trial mode, specially in the context of infection by mutant strains,” the ministry of health and family welfare said in a statement on Saturday.
AstraZeneca plans 2 million doses a week of Covid-19 vaccine for UK: Reports
By Press Trust of India| Posted by Susmita Pakrasi | London
PUBLISHED ON JAN 02, 2021 05:20 PM IST
While AstraZeneca says it expects 2 million doses of the Oxford University vaccine to be ready each week in just over a fortnight, Pfizer BioNTech said the number of doses it has now sent to the UK is “in the millions”.
India approves AstraZeneca’s Covid-19 vaccine
By Reuters| Posted by Susmita Pakrasi | New Delhi
PUBLISHED ON JAN 02, 2021 03:52 PM IST
It is the first Covid-19 vaccine to be approved for emergency use by India, which has the highest number of infections after the United States.
Oxford, AstraZeneca will supply 2mn vaccine doses a week in UK: Report
By Bloomberg| Posted by: Harshit Sabarwal
UPDATED ON JAN 02, 2021 08:17 AM IST
Health Secretary Matt Hancock said earlier this week that only 530,000 doses of the vaccine would be ready on Monday. The Oxford team is frustrated that the poor state of the country’s manufacturing capacity has affected the pace of production, the Times of London said, citing the group member.
SII’s Covishield approval: Efficacy, cost and all about AstraZeneca’s Covid-19 vaccine
By hindustantimes.com | Edited by Kunal Gaurav | Hindustan Times, New Delhi
UPDATED ON JAN 01, 2021 09:03 PM IST
AstraZeneca had signed an agreement with Serum Institute of India (SII) to produce 1 billion doses of its experimental vaccine for low- and middle-income countries.
Govt’s expert panel approves AstraZeneca/Oxford Covid-19 vaccine for emergency use
By Reuters | Posted by Kunal Gaurav | New Delhi
UPDATED ON JAN 01, 2021 06:25 PM IST
The report of approval comes after British regulators on Wednesday granted authorisation to AstraZeneca’s vaccine to provide immunity against the coronavirus disease (Covid-19).
2021: Year of the shot in the Arm
By Binayak Dasgupta | Hindustan Times, New Delhi
UPDATED ON JAN 01, 2021 03:17 AM IST
The experiences in the US, the UK, and several European countries over 2020 have demonstrated that the factory-to-syringe process can throw up several challenges, and that even the most resourceful of nations can struggle with a process that can be as labyrinthine as it needs to be precise.
Covid-19: No data to back UK’s new vaccination plan, says Pfizer
By hindustantimes.com | Edited by Kunal Gaurav | Hindustan Times, New Delhi
UPDATED ON DEC 31, 2020 07:28 PM IST
The UK government announced a new immunisation strategy after a committee recommended inoculating as many people as possible with the first dose before offering others their second dose.